The findings suggest blood-based testing for tau brain deposits is feasible and could be combined with other blood-based assays to improve Alzheimer's testing.
The company will offer a 32-gene polygenic score test to patients in the Osaka, Japan Nakanoshima Clinic, with reporting and patient support help from IxLayer.
The company said its sample preparation technology uses nanomagnetic particles that can reduce the effects of complex interferences in patient samples.
Such an approach could be more specific for Alzheimer's than symptoms-based diagnoses while also allowing for earlier detection and treatment of the condition.
The grant was awarded through the Alzheimer's Drug Discovery Foundation's Diagnostic Accelerator, a partnership between the charity and philanthropic partners.
The agreement gives Quanterix an opportunity to explore the clinical utility of its Nf-l marker without having to move its instruments into the clinical space.
